IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0476164
(1999-12-30)
|
발명자
/ 주소 |
|
출원인 / 주소 |
- Applied Science Fiction, Inc.
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
19 인용 특허 :
89 |
초록
▼
In luminance priority multilayer color film, one of the layers substantially matches the luminance sensitivity of the human eye. This luminance layer distinguishes from prior art color films that have a blue, a green, and a red sensitive layer. This luminance layer has the priority front position to
In luminance priority multilayer color film, one of the layers substantially matches the luminance sensitivity of the human eye. This luminance layer distinguishes from prior art color films that have a blue, a green, and a red sensitive layer. This luminance layer has the priority front position to sense light before being diffused and attenuated by other layers, giving the luminance record enhanced speed and clarity compared to prior art blue-priority color film. In another embodiment, a layered CCD sensor has a top silicon layer that is sensitive to all colors, followed by a yellow filter, a second silicon layer responsive to green and red light only because of the yellow filter, a cyan filter, and a bottom silicon layer receiving only green light. An image from a luminance-priority color sensor inputs to a color space conversion to recover full color. In the preferred embodiment, a luminance layer on top maps to a luminance "Y" value, and underlying color sensitive layers are used in conjunction with the luminance to derive the "U" and "V" chrominance vectors of YUV color space.
대표청구항
▼
In luminance priority multilayer color film, one of the layers substantially matches the luminance sensitivity of the human eye. This luminance layer distinguishes from prior art color films that have a blue, a green, and a red sensitive layer. This luminance layer has the priority front position to
In luminance priority multilayer color film, one of the layers substantially matches the luminance sensitivity of the human eye. This luminance layer distinguishes from prior art color films that have a blue, a green, and a red sensitive layer. This luminance layer has the priority front position to sense light before being diffused and attenuated by other layers, giving the luminance record enhanced speed and clarity compared to prior art blue-priority color film. In another embodiment, a layered CCD sensor has a top silicon layer that is sensitive to all colors, followed by a yellow filter, a second silicon layer responsive to green and red light only because of the yellow filter, a cyan filter, and a bottom silicon layer receiving only green light. An image from a luminance-priority color sensor inputs to a color space conversion to recover full color. In the preferred embodiment, a luminance layer on top maps to a luminance "Y" value, and underlying color sensitive layers are used in conjunction with the luminance to derive the "U" and "V" chrominance vectors of YUV color space. DP-17, said transgene operatively linked to regulatory elements for neuronal expression of said transgene in said transgenic mouse, wherein said transgene expresses human Tau isoforms, and wherein said transgenic mouse develops Tau phosphorylation. 2. The mouse according to claim 1, wherein said genome contains one allele encoding the human TAU gene. 3. The mouse according to claim 1, wherein said genome contains two alleles encoding the human TAU gene. 4. A method of determining if a compound is capable of modulating an Alzheimer's like Tau pathology, comprising administering said compound to a mouse of claim 1, and then examining said mouse for modulation of Alzheimer's like Tau pathology characteristics. 5. A method of determining if a compound is capable of inducing an Alzheimer's like Tau pathology, comprising administering said compound to a mouse of claim 1, and then examining said mouse for development of Alzheimer's like Tau pathology characteristics. 6. A method of screening a compound for activity in treating an Alzheimer's like Tau pathology, comprising administering said compound to a mouse of claim 1, and then examining said mouse for the treatment of said Alzheimer's like Tau pathology. 7. A method of determining if a compound is capable of modulating at least one frontotemporal dementia or Parkinson's-like disease, comprising administering said compound to a mouse of claim 1, and then examining said mouse for modulation of characteristics of the disease. 8. A method of determining if a compound is capable of inducing at least one frontotemporal dementia or Parkinson's-like disease, comprising administering said compound to a mouse of claim 1, and then examining said mouse for the inducement of the disease. 9. A method for screening a compound for activity in treatment of at least one frontotemporal dementia disease or Parkinson's-like disease, comprising administering said compound to a mouse of claim 1, and then examining said mouse for the treatment of said disease. 10. A method of using the mouse of claim 1 to produce a human Tau protein, isoform of the protein, or mutated isoform of the protein, comprising the steps of: allowing the mouse to produce the protein; and removing the protein from the mouse. 11. A transgenic mouse whose germ cells and somatic cells contain an inactive mouse TAU gene, wherein Exon 1 of said inactive mouse TAU gene is deleted and replaced with an expression cassette having a heterologous gene operably linked with a promoter, being oriented in the opposite direction of transcription of said inactive mouse TAU gene, wherein said transgenic mouse is deficient in microtubule assembly and stabilization. 12. A transgenic mouse having a genome comprising a transgene encoding (a) the human TAU gene or (b) a mutated human TAU gene associated with FTDP-17, said transgene operatively linked to regulatory elements for neuronal expression of said transgene in said transgenic mouse, wherein said transgene expresses human Tau isoforms, and wherein said transgenic mouse develops Tau phosphorylation. 13. A method of determining if a compound is capable of modulating an Alzheimer's like Tau pathology, comprising administering said compound to a mouse of claim 12, and then examining said mouse for modulation of Alzheimer's like Tau pathology characteristics. 14. A method of determining if a compound is capable of inducing an Alzheimer's like Tau pathology, comprising administering said compound to a mouse of claim 12, and then examining said mouse for development of Alzheimer's like Tau pathology characteristics. 15. A method of screening a compound for activity in treating an Alzheimer's like Tau pathology, comprising administering said compound to a mouse of claim 12, and then examining said mouse for the treatment of said Alzheimer's like Tau pathology. 16. A method of determining if a compound is capable of modulating at least one frontotemporal dementia or Parkinson's-like disease, compris
※ AI-Helper는 부적절한 답변을 할 수 있습니다.